These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 11854547)

  • 1. Breast cancer prevention.
    Powles TJ
    Oncologist; 2002; 7(1):60-4. PubMed ID: 11854547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?
    Gogas H; Markopoulos C; Blamey R
    Ann Oncol; 2005 Dec; 16(12):1861-6. PubMed ID: 15980159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of breast cancer in the older patient.
    Minton SE
    Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer prevention trials.
    Rhodes DJ; Hartmann LC; Perez EA
    Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
    Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
    J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.
    Ross PJ; Powles TJ
    Clin Breast Cancer; 2001 Apr; 2(1):33-6; discussion 37-40. PubMed ID: 11899380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
    Nelson HD; Smith ME; Griffin JC; Fu R
    Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer.
    Brown PH; Lippman SM
    Breast Cancer Res Treat; 2000 Jul; 62(1):1-17. PubMed ID: 10989982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
    Veronesi U; Maisonneuve P; Rotmensz N; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Lovison F; Gucciardo G; Muraca MG; Pizzichetta MA; Conforti S; Decensi A; Robertson C; Boyle P;
    J Natl Cancer Inst; 2003 Jan; 95(2):160-5. PubMed ID: 12529349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer chemoprevention.
    Rosenbaum Smith SM; Osborne MP
    Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status of antiestrogen breast cancer prevention trials.
    Powles TJ
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.